An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden

Biotechnology and Biotechnological Equipment

Volumn 26, Issue 5, 2012, Pages 3236-3241

  Pavlović, Nebojša ^a   Stanimirov, Bojan ^a   Stojančević, Maja ^a   Paut Kusturica, Milica ^a   Stoimenova, Assena ^b   Goločorbin Kon, Svetlana ^a   Mikov, Momir ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Comparative analysis; Health policy; Legislation; Orphan medicines; Rare diseases; Reimbursement

Indexed keywords

ANTINEOPLASTIC; BULGARIA; CLASSIFICATION SYSTEM; COMPARATIVE ANALYSIS; EU LEGISLATION; EUROPEAN UNION; HEALTH POLICY; PATIENT ACCESS; RARE DISEASE; REIMBURSEMENT;

DISEASES;

LAWS AND LEGISLATION;

EID: 84868266807     PISSN: 13102818     EISSN: None     Source Type: Journal    
DOI: 10.5504/bbeq.2012.0085     Document Type: Review

References (31)

1. Bulgarian Health Act (2004) State Gazette, 70/10 Aug. 2004.
2. Bulgarian Law on Medicinal Products in Human Medicine (2007) State Gazette, 31/13 Apr. 2007.
3. Bulgarian National Plan for Rare Diseases (2009-2013) (genetic, birth defects and noninherited diseases), Ministry of health, Republic of Bulgaria.
4. Council Recommendation (2009) Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02) Offcial Journal of the european communities.
5. Denis A., Mergaert L., Fostier C., Cleemput I., Simoens S. (2010) health Policy, 97(2-3), 173-179.
6. Dental and Pharmaceutical Benefits Agency of Sweden (2011) Medical products database http://www.tlv.se/ beslut/sok-i-databasen (Accessed: Dec. 2011)
7. EURORDIS Proposal for the practical implementation of policy principles to improve access to orphan drugs in the EU (2009) EURORDIS http://www.eurordis.org/ IMG/pdf/Position_PaperCAVOD_2009.pdf (Accessed: Feb. 2012)
8. Heemstra H.E. (2010) EJHP Practice, 16(4), 25-27.
9. International Classification of Diseases (2011) http:// www.who.int/classifcations/icd/en/ (Accessed: Dec. 2011)
10. International Monetary Fund (2011) http://www.imf. org/external/pubs/ft/weo/2012/01/weodata/download. aspx (Accessed: Jan. 2012)
11. List of orphan drugs in Europe (2011) orphanet Report Series, orphan Drugs collection, July 2011.
12. Medicines for rare diseases. european Medicines Agency http://www.ema.europa.eu/ema/index.jsp?curl=pages/ special_topics/general/general_content_000034. jsp&mid=Wc0b01ac058002d4eb (Accessed: Apr. 2012)
13. Ministry of Health in Bulgaria (2011) the Positive Drug list http://www.mh.government.bg (Accessed: Dec. 2011)
14. National Organisation for Rare Diseases of Serbia (2011) http://www.norbs.rs (Accessed: Jan. 2012)
15. Policies for rare diseases and orphan drugs: Kce reports 112C (2009) Belgian Health Care Knowledge Centre https://kce.fgov.be/publication/report/policies-for-rare-diseases-and-orphan-drugs (Accessed: Mar. 2012)
16. Rare Diseases Sweden (2011) http://www. sallsyntadiagnoser.se (Accessed: Dec. 2011)
17. Regulation (1999) Regulation (EC) No 141/2000 of the european Parliament and of the council of 16 December 1999 on orphan drugs.
18. Republic Fund of Health Insurance of Serbia (2011) the list of Medicines http://www.eng.rfzo.rs/index.php/list-of-medicines (Accessed: Dec. 2011)
19. Rinaldi A. (2005) eMBo Reports, 6(6), 507-510.
20. Schneider C.K., et al. (2010) nat. Rev. Drug Discov., 9(3), 195-201.
21. Serbian Games of Chance Act (2011) Offcial Gazette, 88/2011.
22. Serbian Health Insurance Act (2011) Offcial Gazette, 107/2005, 109/2005 and 57/2011.
23. Serbian Law on Healthcare (2011) Offcial Gazette, 107/2005, 72/2009, 88/2010, 99/2010 and 57/2011.
24. Serbian Law on Medicines and Medical Devices (2010) Offcial Gazette, 30/2010.
25. Simoens S. (2011) orphanet J. Rare Dis., 6, 42.
26. Stefanov R., Taruscio D. (2009) Ital. J. Public Health, 7(6), 289-293.
27. Stoimenova A., Manova M., Savova A., Angelovska B., Petrova G. (2011) Biotechnol. Biotech. eq., 25(2), 2418-2423.
28. Tejada P. (2009) Bulgaria at the forefront of rare disease policy http://archive.eurordis.org/article.php3?id_ article=2013 (Accessed: Jan. 2012)
29. The National Board of Health and Welfare of Sweden (2011) http://www.socialstyrelsen.se/rarediseases/aboutrarediseases (Accessed: nov. 2011)
30. Wastfelt M., Fadeel B., Henter J.I. (2006) J. intern. Med., 260(1), 1-10.
31. Westermark K., et al. (2011) nat. Rev. Drug Discov., 10, 341-349.